Specific Requirement of the p84/p110γ Complex of PI3Kγ for Antibody‐Activated, Inducible Cross‐Presentation in Murine Type 2 DCs
Advanced Science · 2024
DOI: 10.1002/advs.202401179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Despoina Koumantou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS EMR8252, Faculté de Médecine site Bichat, Université Paris Cité, Paris, 75018, France. Hauptthemen laut MEDLINE: Dendritic Cells, Cross-Priming, Mice, Inbred C57BL. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, Fondation pour la Recherche Medicale, ICGex NGS platform of the Institut Curie.
Abstract (Originalsprache)
Cross‐presentation by MHCI is optimally efficient in type 1 dendritic cells (DC) due to their high capacity for antigen processing. However, through specific pathways, other DCs, such as type 2 DCs and inflammatory DCs (iDCs) can also cross‐present antigens. FcγR‐mediated uptake by type 2 DC and iDC subsets mediates antibody‐dependent cross‐presentation and activation of CD8 + T cell responses. Here, an important role for the p84 regulatory subunit of PI3Kγ in mediating efficient cross‐presentation of exogenous antigens in otherwise inefficient cross‐presenting cells, such as type 2 DCs and GM‐CSF‐derived iDCs is identified. FcγR‐mediated cross‐presentation is shown in type 2 and iDCs depend on the enzymatic activity of the p84/p110γ complex of PI3Kγ, which controls the activity of the NADPH oxidase NOX2 and ROS production in murine spleen type 2 DCs and GM‐CSF‐derived iDCs. In contrast, p84/p110γ is largely dispensable for cross‐presentation by type 1 DCs. These findings suggest that PI3Kγ‐targeted therapies, currently considered for oncological practice, may interfere with the ability of type 2 DCs and iDCs to cross‐present antigens contained in immune complexes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS EMR8252, Faculté de Médecine site Bichat, Université Paris Cité, Paris, 75018, France.
- Laboratoire d'Excellence Inflamex, Université Paris Cité, Paris, 75018, France.
- CNRS, INSERM, Institut Cochin, Paris, 75014, France.
- Institut Pasteur, RNA Biology of Fungal Pathogens, Université Paris Cité, Paris, 75015, France.
- INSERM UMR 1048, I2MC, Toulouse, 4 31432, France.
- Department of Biomedicine, University of Basel, Mattenstrasse 28, Basel, CH-4058, Switzerland.
ORCID-Profile: Loredana Saveanu
Förderung
- Agence Nationale de la Recherche
- Fondation pour la Recherche Medicale
- ICGex NGS platform of the Institut Curie
- SiRIC-Curie program
- Swiss National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Koumantou, D., Adiko, A. C., Bourdely, P., Nugue, M., Boedec, E., El-Benna, J., Monteiro, R., Saveanu, C., Laffargue, M., Wymann, M. P., Dalod, M., Guermonprez, P., & Saveanu, L. (2024). Specific Requirement of the p84/p110γ Complex of PI3Kγ for Antibody‐Activated, Inducible Cross‐Presentation in Murine Type 2 DCs. Advanced Science. https://doi.org/10.1002/advs.202401179
Vancouver
Koumantou D, Adiko AC, Bourdely P, Nugue M, Boedec E, El-Benna J, et al. Specific Requirement of the p84/p110γ Complex of PI3Kγ for Antibody‐Activated, Inducible Cross‐Presentation in Murine Type 2 DCs. Advanced Science. 2024. doi:10.1002/advs.202401179
BibTeX
@article{Koumantou2024,
author = {Koumantou, Despoina and Adiko, Aimé Cézaire and Bourdely, Pierre and Nugue, Mathilde and Boedec, Erwan and El-Benna, Jamel and Monteiro, Renato and Saveanu, Cosmin and Laffargue, Muriel and Wymann, Matthias P and Dalod, Marc and Guermonprez, Pierre and Saveanu, Loredana},
title = {Specific Requirement of the p84/p110γ Complex of PI3Kγ for Antibody‐Activated, Inducible Cross‐Presentation in Murine Type 2 DCs},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202401179}
}
EUVIMED